Results 31 to 40 of about 143,566 (359)
Frontiers in Oncology, 2019 Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially ...
Jan-Michael Werner +14 more
doaj +1 more source
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis [PDF]
, 2018 The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), the 2015 ...
Calleja Cervantes, M. E. +4 more
core +1 more source
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology [PDF]
, 2020 Combination immunotherapy (CIT) is currently applied as a treatment for different cancers and is proposed as a cure strategy for chronic viral infections. Whether such therapies are efficient during an acute infection remains elusive.
Akhmetzyanova, Ilseyar [u.v.m.] +9 more
core +1 more source
Metabolic Implications of Immune Checkpoint Proteins in Cancer
Cells, 2022 Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response.
Elizabeth R. Stirling +5 more
doaj +1 more source
Checkpoint Blockade in Cancer Immunotherapy [PDF]
, 2006 The progression of a productive immune response requires that a number of immunological checkpoints be passed. Passage may require the presence of excitatory costimulatory signals or the avoidance of negative or coinhibitory signals, which act to dampen or terminate immune activity.
Alan J, Korman +2 more
openaire +2 more sources
Frontiers in Immunology, 2020 Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors.
Yuxiao Song +5 more
doaj +1 more source
Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The Galectin-3 signature in NSCLCs [PDF]
, 2019 Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking.
Bartolazzi A. +4 more
core +1 more source
Neoplasia: An International Journal for Oncology Research, 2019 Immune checkpoint inhibitors have shown clinical benefit in several cancer entities including metastatic microsatellite instable colorectal carcinomas. However, for the majority of metastatic colorectal carcinomas the potential and limitations of immune ...
E Fiegle +7 more
doaj +1 more source
Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model
Frontiers in Oncology, 2020 Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low.
Evelyn Sirait-Fischer +13 more
doaj +1 more source
CD8+ T-cell responses in vaccination: Reconsidering targets and function in the context of chronic antigen stimulation [PDF]
, 2018 Cytotoxic CD8 T cells play important roles in eliminating infected and transformed cells. Owing to their potential for therapeutic applications, significant efforts are dedicated toward developing CD8 T cell-based vaccines.
Cosma, Gabriela L., Eisenlohr, Laurence
core +2 more sources